CX3CL1 and atherosclerosis: Fractalkine/CX3CL1 expression has been detected on activated endothelial cells, smooth muscle cells (SMCs), macrophages and platelets, and is involved in the development of numerous inflammatory pathologies including atherosclerosis, rheumatoid arthritis, or graft rejection [7–13].